Citigroup
BEAT

Citigroup’s BioTelemetry, Inc. BEAT Stock Holding History

Citigroup’s Portfolio BEAT Stock Details BEAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-200
Closed -$14K – 7903
2020
Q4 		$14K Sell
200
-100
-33% -$5.24K ﹤0.01% 6849
2020
Q3 		$14K Sell
300
-15,100
-98% -$631K ﹤0.01% 6437
2020
Q2 		$696K Buy
15,400
+1,200
+8% +$53.8K ﹤0.01% 3923
2020
Q1 		$547K Buy
14,200
+7,400
+109% +$341K ﹤0.01% 3797
2019
Q4 		$315K Sell
6,800
-13,800
-67% -$598K ﹤0.01% 4814
2019
Q3 		$839K Sell
20,600
-1,200
-6% -$51.8K ﹤0.01% 3841
2019
Q2 		$1.05M Buy
21,800
+1,700
+8% +$89.4K ﹤0.01% 3566
2019
Q1 		$1.26M Buy
20,100
+12,400
+161% +$852K ﹤0.01% 3159
2018
Q4 		$460K Sell
7,700
-1,500
-16% -$90.1K ﹤0.01% 4211
2018
Q3 		$593K Buy
9,200
+2,200
+31% +$123K ﹤0.01% 4078
2018
Q2 		$315K Buy
7,000
+400
+6% +$15.9K ﹤0.01% 4581
2018
Q1 		$205K Buy
6,600
+1,600
+32% +$52.6K ﹤0.01% 4943
2017
Q4 		$150K Buy
5,000
+1,000
+25% +$29K ﹤0.01% 5294
2017
Q3 		$132K Buy
4,000
+2,300
+135% +$79.7K ﹤0.01% 5340
2017
Q2 		$57K Buy
+1,700
New +$50.7K ﹤0.01% 5706

Other funds holding BEAT

LCM
Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

Citigroup's BEAT Position: Q1 2021 in Review

Citigroup sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 15,754 shares — an estimated $1.14M sold.

Citigroup first reported a position in BEAT in Q2 2013 and held it in 28 quarters. The position peaked at $4.27M in Q3 2018. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

  • Citigroup reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
  • Citigroup sold 15,754 BioTelemetry, Inc. shares in Q1 2021, an estimated $1.14M.
  • Citigroup first reported a position in BioTelemetry, Inc. in Q2 2013 and held it in 28 quarters.
  • Citigroup's BioTelemetry, Inc. position peaked at $4.27M in Q3 2018.
  • 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Citigroup's 13F filing for Q1 2021, filed 13 May 2021.